Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Juan Cueva, Jerónimo Martínez-García et al.|The Lancet|2023

Cited by 225